Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines by Tscharke, David C. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
ARTICLE
 
95
 
JEM Vol. 201, No. 1, January 3, 2005 95–104 www.jem.org/cgi/doi/10.1084/jem.20041912
 
Identiﬁcation of poxvirus CD8
 
 
 
 T cell 
determinants to enable rational design 
and characterization of smallpox vaccines
 
David C. Tscharke,
 
1,2
 
 Gunasegaran Karupiah,
 
3
 
 Jie Zhou,
 
3
 
 Tara Palmore,
 
1 
 
Kari R. Irvine,
 
1
 
 S.M. Mansour Haeryfar,
 
1
 
 Shanicka Williams,
 
1
 
 John Sidney,
 
4
 
 
 
Alessandro Sette,
 
4 
 
Jack R. Bennink,
 
1
 
 and Jonathan W. Yewdell
 
1
 
1
 
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 
MD 20892
 
2
 
EBV Biology Laboratory, Division of Immunology and Infectious Diseases, Queensland Institute of Medical Research, Herston, 
QLD 4006, Australia
 
3
 
Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, 
ACT 2601, Australia
 
4
 
Division of Translational Immunology and Biodefense, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121
 
The large size of poxvirus genomes has stymied attempts to identify determinants recognized 
by CD8
 
 
 
 T cells and greatly impeded development of mouse smallpox vaccination models. 
Here, we use a vaccinia virus (VACV) expression library containing each of the predicted 258 
open reading frames to identify five peptide determinants that account for approximately 
half of the VACV-specific CD8
 
 
 
 T cell response in C57BL/6 mice. We show that the primary 
immunodominance hierarchy is greatly affected by the route of VACV infection and the 
poxvirus strain used. Modified vaccinia virus ankara (MVA), a candidate replacement smallpox 
vaccine, failed to induce responses to two of the defined determinants. This could not be 
predicted by genomic comparison of viruses and is not due strictly to limited MVA replication 
in mice. Several determinants are immunogenic in cowpox and ectromelia (mousepox) virus 
infections, and immunization with the immunodominant determinant provided significant 
protection against lethal mousepox. These findings have important implications for 
understanding poxvirus immunity in animal models and bench-marking immune responses 
to poxvirus vaccines in humans.
 
In the late 1700s, Edward Jenner published the
seminal observation that infection with animal
poxviruses protects humans against smallpox
(1). Though similar practices had been fol-
lowed for centuries by other societies around
the world, Jenner was the first to apply the sci-
entific method to evaluating efficacy. In so do-
ing, he laid the foundations for both the eradi-
cation of smallpox and for the discipline of
immunology.
Despite its historic origins, current under-
standing of the molecular basis for cross-pro-
tection between heterologous poxviruses is
woefully incomplete. This is particularly the
case for antigens recognized by T cells, al-
though they are assumed to play an important
role in immunity (2–4). The neglect stems
partly from the daunting size of poxvirus ge-
nomes and from the lack of a pressing need to
understand poxvirus immunology after the
eradication of smallpox (2). Recent improve-
ments in molecular methods and determinant
prediction have made genome size less of an
obstacle. The specter of variola virus (VARV),
the causative agent of smallpox, being used as a
bioweapon has eliminated complacency about
human poxvirus immunity (5). The current
live vaccinia virus (VACV)-based smallpox
vaccine, while remarkably effective, is associ-
ated with mild to severe complications and
safer alternatives are required.
As a consequence, identification of human
T cell determinants of VACV, the current
smallpox vaccine, is now underway. To date,
papers have been limited to a few determinants
presented by a single restricting class I mole-
cule (6–8). Although this work is important
for characterizing human responses to safer
vaccines, the biological relevance of responses
to these determinants cannot be tested. Fortu-
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nately, there are animal models to shed light on the problem
of cross-protection between heterologous poxviruses. For
example, just as VACV protects humans against smallpox,
this same virus protects mice against mousepox (9, 10).
Mousepox is caused by ectromelia virus (ECTV), a
mouse pathogen closely related to VACV and VARV (11,
12). Current understanding of smallpox pathogenicity owes
much to pioneering work with mousepox (13, 14) and more
recent work has taught us much about immunity in systemic
poxvirus disease (15–17). Alternative models for lethal pox-
virus disease in mice have also been exploited, including in-
tranasal VACV (6, 8, 18–20) and cowpox virus (CPXV; ref-
erence 21) infection. Although the specificities of T cells that
contribute to protection of humans against smallpox and
mice against various poxviruses will not be identical due to
differences in antigen processing and presentation and T cell
receptor repertoires, the basic principles underlying protec-
tion are likely to be similar. Due to the sophistication of the
mouse model for immunity, many important questions
about the basic immunology of poxvirus protection are best
addressed at this time in mouse models. These include assess-
ment of the importance of individual effector mechanisms
and the degree and mechanism of protection afforded by
smallpox vaccine candidates.
A critical step in refining the mouse model is to define
poxvirus determinants recognized by CD8
 
 
 
 T cells and de-
termine their role in protective immunity. Here, we provide
the original description of poxvirus determinants recognized
by mouse CD8
 
 
 
 T cells, and their biological relevance in
protection against lethal poxvirus infections.
 
RESULTS
Identification of VACV CD8
 
 
 
 T cell determinants in mice
 
To identify immunogenic VACV gene products, we gener-
ated an expression library of 258 predicted open reading
frames (ORFs) and highly transfectable cells (human 293
cells) expressing H-2K
 
b
 
 or D
 
b
 
. Cells transfected with indi-
vidual plasmids were tested for their ability to induce IFN-
 
 
 
expression in CD8
 
 
 
 T cells derived from C57BL/6 mice in-
fected i.p. with VACV 7 d previously (Fig. 1 a). Five anti-
genic VACV ORFs were discovered, three restricted by
H-2K
 
b
 
 and two by H-2D
 
b
 
 (Table I). For two ORFs, A19L
and A47L, this is the first empirical evidence that they are
expressed during infection. Ironically, of the known genes,
two (B8R and K3L) are involved in virus evasion of host in-
terferon responses (22). Whether this apparent targeting of
immune modulators by CD8
 
 
 
 T cells is a general phenome-
non or a quirk of the mouse model used requires more de-
terminants to be mapped in mice and other species.
Antigenic VACV ORFs were analyzed in silico for pep-
tides matching the relevant class I peptide-binding motif.
Synthetic peptides for predicted determinants were tested for
their ability to bind the relevant class I allomorph and to ac-
tivate CD8
 
 
 
 T cells from VACV-infected mice (Table I).
None of the predicted A42R peptides were immunogenic,
which led to testing subclones expressing gene fragments
(residues 1–48, 1–82, 75–end, and 107–end) and ultimately a
second round of in silico prediction resulting in identifica-
tion of YAPVSPIVI as the determinant.
Synthetic peptides for each of the five mapped determi-
nants were antigenic at 
 
 
 
10
 
 
 
10
 
 M (Fig. 1 b) when tested
for their ability to activate primary VACV-specific CD8
 
 
 
 T
cells. Peptide-specific CD8
 
 
 
 T cell cultures were generated
by in vitro stimulation of splenocytes from VACV-infected
mice over several weeks. Cultures stimulated with the five
peptides were found to recognize VACV-infected DC2.4
cells and VACV-infected 293 expressing the correct restric-
Figure 1. Mapping and characterizing CD8  T cell determinants. 
Mice were infected with 106 PFU VACV i.p. and 7 d later, purified CD8  T 
cells (a) or splenocytes (b) were used in ICS assays. (a) Examples taken 
from the original screening assays used to identify VACV genes with Kb-
restricted CD8  T cell determinants. 293KbC2 cells transfected with VACV 
genes (top left) as part of a 96-well array were used as stimulators. IFN-  , 
CD8  events as a percent of all CD8  events is shown in the gates drawn 
around the IFN-   population. (b) Antigenic potency of synthetic peptides. 
DC2.4 cells pulsed with the peptides at the indicated concentrations were 
used as stimulators in ICS assays. Data are expressed as the percent of maxi-
mum stimulation; lines are drawn to indicate peptide concentrations in-
ducing half-maximal CD8  T cell activation. Peptide titrations were repeated. 
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tion element (unpublished data). Similar cultures recog-
nized 293 cells expressing the appropriate restriction ele-
ment transfected with the source VACV gene, but not
another gene, or the source gene where the wrong restric-
tion element was present (unpublished data). This strongly
suggests that the peptides identified represent bona fide vi-
rus-encoded determinants generated by antigen processing
pathways and not spuriously cross-reacting peptides. We
note that the odds of this latter possibility increase with in-
creasing genome size of the immunogen and might prove
to be particularly relevant to poxviruses and other large
DNA viruses.
 
Contribution of mapped determinants to total response
 
We determined the contribution of these determinants to
the total acute (day 7; Fig. 2 a) and memory (day 21; Fig. 2
b) CD8
 
 
 
 T cell response to VACV by intracellular cytokine
staining (ICS) of splenocytes tested ex vivo. Uninfected
mice failed to detectably respond to any of the peptides (un-
published data). 7 d after i.p. infection, B8R
 
20-27
 
 elicited a
response from 10–15% of all splenic CD8
 
 
 
 T cells, amount-
ing to a staggering 10
 
7
 
 cells in the spleen alone. Other deter-
minants elicited a more modest response; in general, K3L
 
6-15
 
was the next strongest followed by A47L
 
138-146
 
, A42R
 
88-96
 
,
and A19L
 
47-55
 
. Occasionally, in individual mice, the order of
K3L
 
6-15
 
 and A47L
 
138-146
 
 was swapped in the immunodomi-
nance (ID) hierarchy, but A19L
 
47-55
 
 was always at the bot-
tom. The stability of the VACV ID hierarchy in individual
mice is similar to that seen with influenza virus (23). Com-
paring determinant-specific responses with the total VACV-
specific response shows that B8R
 
20-27
 
, the immunodomi-
nant determinant (IDD), alone stimulates 
 
 
 
25% of the total
response. When combined with the four subdominant de-
terminants (SDDs), this accounts for up to 40% of the total
response.
As expected, CD8
 
 
 
 T cell numbers decreased in memory
CD8
 
 
 
 T cells, which were also measured ex vivo by ICS. The
ID hierarchy was slightly altered, due to a less pronounced de-
crease in A47L
 
138-146
 
-specific CD8
 
 
 
 T cells. Similar relative
sparing of CD8
 
 
 
 T cells specific for SDDs in memory has
been observed previously (24). Altogether, the CD8
 
 
 
 T cells
specific for the defined determinants account for 
 
 
 
30% of the
total anti-VACV memory CD8
 
 
 
 T cell response.
 
Route of infection affects ID
 
Smallpox vaccination has been performed for centuries by
dermal scarification, whose simplicity probably contributed
to smallpox eradication. To our surprise, after scarification
with VACV, B8R
 
20-27
 
-specific responses were enhanced,
whereas responses to SDDs were depressed (Fig. 3 a). In-
deed, in most mice, responses to the two weakest SDDs
were reduced to the limit of detection. The enhanced re-
 
Table I.
 
Immunogenic proteins, peptides tested, and CD8
 
 
 
 T cell epitopes
 
Gene H-2 Function Time
 
a
 
Peptides tested
 
b
 
IC
 
50
 
 (nM)
 
c
 
Determinant
 
d
 
Name
 
e
 
B8R
 
K
 
b
 
soluble IFN-
 
 
 
 receptor early TSYKFESV 0.19 TSYKFESV B8R
 
20-27
 
WQTMYTNV 6.6
ISLKNYGI 16
LAVLFINSI 28
KVEEYCTGL 129
 
A19L
 
K
 
b
 
unknown – VSLDYINTM 0.77 VSLDYINTM A19L
 
47-55
 
SDITKVSL 1,261
VKISDITKV 4,930
 
A47L
 
K
 
b
 
unknown – TIQRFSSL 1.1
AAFEFINSL 1.3 AAFEFINSL A47L
 
138-146
 
ATIQRFSSL 1.3
VSDLYTSM 7.0
LTPIFSDLL 7.3
 
A42R
 
D
 
b
 
profilin homologue late YAPVSPIVI 0.24 YAPVSPIVI A42R
 
88-96
 
FAKINPGEI 54
LMDENTYAM 767
MYAPVSPIVI 1,266
FAKINPGEII 2,071
 
K3L
 
D
 
b
 
IFN resistance early YSLPNAGDVI 0.22 YSLPNAGDVI K3L
 
6-15
 
YSLPNAGDV 102
YIDVNYKRM 5,138
 
a
 
Class of VACV gene as published: early, late, or unknown.
 
b
 
Top five peptides (by H-2 binding) predicted for each gene. Total peptides tested: B8R, 28; A19L, 3; A47L, 45; A42R, 7; and K3L, 3.
 
c
 
Peptide binding to relevant H-2 molecule.
 
d
 
CD8
 
 
 
 T cell determinant as determined by T cell assays.
 
e
 
Name used for determinant is gene name followed by amino acid position. 
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sponse to B8R
 
20-27
 
 is strikingly demonstrated by comparison
to the total VACV-specific response; after dermal scarifica-
tion, 
 
 
 
50% of CD8
 
 
 
 T cells are specific for B8R
 
20-27
 
. To
test this apparent suppression of SDD responses more rigor-
ously, the ratio of the sum of the SDD-specific responses to
the IDD-specific response was calculated using data from in-
dividual mice from several experiments to provide a larger
sample size (Fig. 3 b). The mean of this ratio was signifi-
cantly different (P 
 
  
 
0.0013) between mice infected by the
i.p. and dermal routes. Finally, responses to all determinants
contribute nearly 60% of the total primary CD8
 
 
 
 T cell re-
sponse induced by scarification.
 
Dryvax immunized mice respond to all mapped determinants
 
Until this point, we had exclusively used the WR strain of
VACV, which was derived from the New York City Board
of Health (NYCBH) vaccine strain by serial passage in mice
and tissue culture (25). Dryvax (Wyeth Laboratories), the
smallpox vaccine currently available in the USA, is the NY-
CBH strain propagated on the skin of calves. All determinants
were immunogenic in mice infected i.p. with Dryvax. The
ID hierarchy was similar to that found with WR; the only de-
terminant with responses that differed significantly was K3L
 
6-15
 
(P 
 
  
 
0.0158; Fig. 4 a). A screen of the VACV ORF library
Figure 2. CD8  T cell responses to VACV determinants and VACV-
infected cells. (a and b) Mice were immunized i.p. with 106 PFU of VACV 
strain WR and responses measured by ICS 7 (a) and 21 (b) d later. 
(left) Graphs show the percent of splenic CD8  T cells that produce IFN-  
in ex vivo stimulations with the individual peptides indicated (name of gene 
shown). (right) Graphs compare a summation of the peptide data with the 
percent of splenic CD8  T cells that produce IFN-  in ex vivo stimulations 
with VACV-infected DC2.4 cells. Data are means and SEM from groups of 
three mice. Experiments have been repeated with similar results.
Figure 3. CD8  T cell responses after infection by dermal scarification. 
(a) Mice were immunized by tail scarification and application of VACV at 
107 PFU/ml, and responses were measured by ICS 7 d later. (left) Graph 
shows the percent of splenic CD8  T cells that produce IFN-  in ex vivo 
stimulations with the individual peptides indicated (name of gene shown). 
Graph on right compares a summation of the peptide data with the percent 
of splenic CD8  T cells that produce IFN-  in ex vivo stimulations with 
VACV-infected DC2.4 cells. Data are means and SEM from groups of three 
mice; the experiment was repeated with similar results. (b) Total response 
to SDDs as a ratio of the response to the IDD in acute infection by i.p. 
(peritoneal) and dermal scarification (dermal) routes. SDDs:IDD ratio was 
calculated for individual mice from several experiments (i.p., n   19; dermal 
scarification, n   6), and means and SEM were plotted. p-value was deter-
mined by Students’ t test.
Table II. Conservation of immunogenic proteins and determinants across poxvirus species and strains
VACV-WR VACV-MVAa CPXV-BR ECTV-Mos VARV-Bshb
Gene Determinant Genec Determinantd Gene Determinant Gene Determinant Gene Determinant
B8R TSYKFESV NA/176 Y 202 Y 158 Y B8R Y
A19L VSLDYINTM 130 Y 152 Y 122 Y A20L Y
A47L AAFEFINSL 160 Y 185 Y 146 Ae J1L Y
A42R YAPVSPIVI 154R Y 179 Y 141 Y A45R Y
K3L YSLPNAGDVI 024 Y 043 Y NA Y C3L Af
aVACV-MVA: two available sequences (U94848 and AY603355) agree except for B8R. CPX-BR: CPXV-Brighton red, ECTV-Mos: ECTV-Moscow, VARV-Bsh: VARV-Bangladesh.
bVARV does not infect mice; determinant conservation is shown only for completeness.
cGene name given where annotated; NA: gene not included in annotation.
dY: Determinant conserved in genomic sequence; gene may or may not be intact or expressed.
eA: Determinant is altered to ATFEFINSL.
fA: Determinant is altered to YSLPNVGDVL.JEM VOL. 201, January 3, 2005 99
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performed with splenocytes from Dryvax immunized mice
failed to identify novel determinants (unpublished data).
Conservation of immunogenic proteins and determinants 
across poxvirus strains and species
We searched databases for the presence of immunogenic
ORFs in VACV strain modified vaccinia virus ankara
(MVA); ECTV strains Naval and Moscow; CPXV strains
Brighton red and GRI-90; and VARV strains Bangladesh,
India, and VARV minor. Results for different strains from
the same species (with the exception of VACV) were identi-
cal, so only data from a representative strain of each are in-
cluded in Table II. All poxviruses have a range of broken,
truncated, or otherwise incomplete ORFs, whose annota-
tions are inconsistent. Therefore, where immunogenic ORFs
were not annotated (e.g. B8R in the original MVA se-
quence), we looked for conservation of the sequence encod-
ing the determinants in the genome. In the case of B8R in
MVA, the determinant is encoded upstream of the inactivat-
ing truncation of the ORF and a more recent sequence has
included this ORF in the annotation. Because the promoter
sequences are conserved, the determinant should be expressed.
On the other hand, K3L function is not conserved in ECTV
and while the determinant encoding sequence is present,
there are sequence changes in the promoter region that
could interfere with expression.
ID hierarchy is altered in MVA-immunized mice
MVA is a highly attenuated strain of VACV being developed
as a smallpox vaccine replacement (26) and is a potential vec-
tor for recombinant vaccines (27). To determine if conserva-
tion of genes/determinants in published poxvirus genomes
equates with conservation of CD8  T cells’ immunogenicity
and dominance hierarchy, we measured CD8  T cell re-
sponses to i.p. infection with MVA (Fig. 4 b). Though
B8R20-27 maintained its IDD status, responses to the SDDs
were greatly altered relative to WR. Responses to all SDDs
were significantly different in MVA compared with WR-
infected mice (P   0.0006 for A47L138-146, A42R88-96, and
K3L6-15 and P   0.014 for A19L47-55). A19L47-55, usually the
weakest determinant, was the second strongest after MVA
immunization at  2% of all CD8  T cells, whereas re-
sponses to K3L6-15 were lower and those to A47L138-146 and
A42R88-96 were at background levels. The lack of response
to the latter two determinants cannot be attributed to ge-
netic variation in the determinants in the MVA strain we
used as determined by DNA sequencing. The total VACV-
specific response was slightly lower after MVA infection than
WR infection, but higher than in Dryvax-immunized mice
(unpublished data). We also screened the VACV ORF li-
brary with splenocytes from MVA-infected mice, but no
new CD8  T cell determinant–bearing gene products were
identified (unpublished data).
These data demonstrate that first, the presence of con-
served determinants in conserved ORFs predicted to be
expressed provides no guarantee of immunogenicity and,
second, the ID hierarchy can be affected by genomic differ-
ences in poxviruses not predicted to effect the expression of
determinants.
Responses to mapped determinants are found in mice 
immunized with attenuated VACVs
The striking difference in ID hierarchies between WR and
MVA could stem from the attenuation of MVA, which, in
contrast with WR/Dryvax, is capable of only marginal repli-
cation in mammalian cells in vitro and in vivo (27, 28). To
examine the relationship between virus attenuation and ID
hierarchy, we infected mice with a VACV that only ex-
presses the essential viral structural gene A17L in the pres-
ence of IPTG (iA17L; reference 29) and, therefore, cannot
Figure 4. CD8  T cell responses to VACV determinants after immu-
nization with different strains. Mice were immunized i.p. with 106 WR 
(a and b), 106 PFU of Dryvax (a), 5   107 FFU of MVA (b), and 5   106 PFU 
of iA17L and 106 PFU Vsc8 (TK ) (c), and CD8  T cell responses to peptides 
were measured by ICS after 7 d. Data are percent of splenic CD8  T cells 
that produce IFN-  in ex vivo stimulations with the peptides derived from 
the VACV genes shown. Means and SEM of four (a and b) and three (c) 
mice are plotted; all data have been independently replicated.DEFINITION OF POXVIRUS CD8  T CELL DETERMINANTS | Tscharke et al. 100
replicate in vivo. This virus, like many recombinant VACVs,
also lacks thymidine kinase and so a thymidine kinase–defi-
cient VACV (VACV-TK ; reference 30) is shown as a con-
trol for this experiment. VACV-TK  is replication compe-
tent but less pathogenic than WR in vivo (31), and several
thymidine kinase–deficient VACVs have been found to have
similar ID hierarchies to WR (unpublished data). Despite
being unable to replicate in vivo, iA17L generated an ID hi-
erarchy highly similar to TK  (Fig. 4 c) or WR (Figs. 2 a
and 4, a and b). We conclude that attenuation per se does
not lead to significant alterations in ID hierarchy to poxvi-
ruses and cannot account for the alterations between CD8 
T cell responses to VACV and MVA.
Identification of VACV-CD8  T cell determinants 
by ECTV and CPXV
The protection afforded by the smallpox vaccine relies on
cross-reactivity between VACV and VARV. To examine
cross-reactivity of poxvirus-specific CD8  T cell determi-
nants in a mouse system, we extended our characterization
of CD8  T cell responses to include ECTV and CPXV (Fig.
5). B8R20-27 maintained IDD status in responses to both vi-
ruses but generated weaker responses when compared with
VACV, raising the possibility of other dominant determi-
nants in these viruses. ECTV failed to induce reliable re-
sponses to A42R88-96 or K3L6-15. The latter was expected
from genomic analysis (Table II). The anti-ECTV response
to A47L138-146 was of interest due to a predicted sequence
change in the determinant in the second residue (A to T).
Using a synthetic version of the altered peptide we con-
firmed its cross-reactivity with ECTV and VACV-specific
CD8  T cells (unpublished data).
For CPXV infection, B8R20-27, A47L138-146, and K3L6-15
consistently generated responses in individuals, whereas
A19L47-55 responses were at the limits of detection. The dif-
ficulty to demonstrate A42R88-96 immunogenicity in these
experiments may be a reflection of the subcutaneous route of
infection, as responses to this determinant were also equivo-
cal after VACV infection by dermal scarification.
Vaccination with the immunodominant VACV determinant 
leads to partial protection against mousepox
Finally, we examined the ability of CD8  T cells primed by
immunization with DC exposed to the IDD B8R20-27, to
protect against lethal ECTV challenge. In a first experiment,
we found that B8R20-27-pulsed DCs induced low but mea-
surable CD8  T cell responses (unpublished data) and protec-
tion from intranasal challenge with ECTV that was significant
(P   0.0279), but incomplete (Fig. 6 a). This protection was
confirmed in a second experiment controlled with groups of
mice immunized with TK  VACV and DCs pulsed with an
irrelevant peptide (P   0.0196; Fig. 6 b). These data demon-
strate that the IDD, B8R20-27, not only cross-reacts amongst
poxvirus species but is also cross-protective.
DISCUSSION
The large coding capacity of poxvirus genomes presents a
challenge for determinant mapping. Consequently, it is
tempting to use various criteria to winnow the number of
Figure 5. Responses to VACV CD8  T cell determinants after ECTV 
and CPXV infection. Mice were immunized s.c. in the rear leg shank with 
103 PFU of ECTV (black bar), VACV strain WR (diagonally striped bar), and 
CPXV (white bar) and CD8  T cell responses to peptides were measured by 
ICS after 7 d (VACV and CPXV) and 8 d (ECTV). Data are percent of splenic 
CD8  T cells that produce IFN-  in ex vivo stimulations with the individual 
peptides shown and are means and SEM of groups of four mice. Experiment 
was repeated with similar results.
Figure 6. Immunization with peptides and mousepox challenge. 
(a) Unimmunized mice (n   5) or mice immunized with DCs pulsed with 
B8R20-27 3 wk previously (n   8) were challenged with 300 PFU ECTV 
intranasally and monitored for survival. (b) Groups of 10 mice immunized 
with VACV TK  or DCs pulsed with B8R20-27 or herpes simplex virus gB498–505 
were challenged as in panel a. In both experiments, splenic DCs were 
matured with LPS overnight before pulsing with peptides and 5   105 
cells were administered i.v. per mouse. After challenge mice killed when 
moribund were counted as mortality events, p-values were generated by 
comparison of survival curves using the log-rank test.JEM VOL. 201, January 3, 2005 101
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genes to be considered. Virus late genes are often excluded
in determinant screens (6, 7). VACV-determinant mapping
projects also use conservation between orthopoxviruses as a
determinant selection criteria (6–8). Our results show that
both criteria are seriously flawed. We discovered an immu-
nogenic determinant in A42R, considered to be a late gene
product (32). In addition, we provide several examples in
which the immunogenicity of determinants in poxviruses
cannot be predicted from the conservation of their sequence
and integrity of their source ORFs according to sequences in
the available databases. Furthermore, conserved determinants
may easily be missed because fragments of known genes are
not always included in annotations of poxvirus genome, as
was the case for the B8R20-27 determinant from B8R in the
original MVA sequence. Finally, practical considerations
aside, a complete understanding of cross-protection requires
knowledge not only of the determinants two viruses have in
common, but the ones that are unique to each infection.
The identification of the immunogenic determinants in
poxviruses should greatly facilitate development of the
mouse model for smallpox vaccination and also the utility of
mouse poxvirus infections for understanding viral immunity.
The latter point is underscored by our observation that the
ID hierarchy varies with the route of infection, the first
observation of its kind to our knowledge. It will be of great
interest to determine the underlying mechanism. It could re-
flect route-dependent differences in the identity of antigen-
presenting cells that activate CD8  T cells, the nature of
antigen presented (e.g., direct vs. cross-priming), or the rep-
ertoire of CD8  T cells that interact with antigen-presenting
cells in the locale where priming occurs. Understanding
route-dependent effects on immunogenicity is critical to in-
terpreting vaccine trials such as the recent paper comparing
intramuscular immunization with MVA to standard scarifica-
tion with Dryvax (33).
We found that the ID hierarchy amongst SDDs was
greatly altered in mice immunized with MVA compared
with WR. Furthermore, responses to two VACV determi-
nants that were always detectable in mice infected by the i.p.
route with WR were at background levels when MVA was
used. Experiments with another highly attenuated VACV
(iA17L) demonstrate that the results found with MVA can-
not be attributed per se to decreased replication in vivo. Se-
quence database searches found these two determinants and
their genes intact and expected to be expressed in two sepa-
rate isolates of MVA, one of which is derived from the same
source as our MVA stock. Furthermore, DNA sequencing
of our virus stock revealed no alterations in the determi-
nants. It is more likely that the altered ID hierarchy is related
to one or more of the many genomic deletions and other
changes in MVA compared with WR (34). It is possible that
MVA encodes a novel IDD that suppresses other responses
via immunodomination (23). Alternatively, genes encoding
the cryptic determinants may not be expressed at immuno-
genic levels by MVA in vivo. Irrespective of the cause, the
finding that responses were not predictable on the basis of
sequence information challenges assumptions about conser-
vation of CD8  T cell responses between related viruses and
underscores the need for empirical data. It also raises the im-
portant issue of the degree of overlap between cellular im-
mune responses to Dryvax and potential smallpox vaccine
replacements.
Using the VACV/ECTV model, we identify the first
VACV-CD8  T cell determinant that may mediate cross-
protection against a lethal systemic disease with a heterolo-
gous poxvirus. This extends prior studies with individual
CD8  T cell determinants using VACV challenge models in
HLA-A2 transgenic mice (6, 8) and shows the potential of
CD8  T cells to mediate protection against poxvirus disease.
Immunization with B8R20-27 synthetic peptide provided in-
complete protection in our challenge model, but we note
that the number of CD8  T cells induced by peptide vacci-
nation was at least 50-fold less than after VACV infection,
and inducing higher CD8  T cell responses could well pro-
vide better protection. Furthermore, although our data show
a potential basis for cross-protection between orthopoxvi-
ruses, more work is needed to understand the roles of CD8 
T cells and other effector mechanisms in the context of cur-
rent VACV-based vaccines.
MATERIALS AND METHODS
Viruses and cell lines. VACV strains WR, MVA, Vsc8 (30), and iA17L
(29); ECTV strain Moscow; and CPXV strain Brighton were grown and ti-
trated using standard methods. Dryvax smallpox vaccine was obtained from
the Centers for Disease Control, Atlanta. Titred stocks of MVA and titra-
tion of Dryvax were provided by L. Wyatt (National Institute of Infectious
Diseases [NIAID], Bethesda, MD). 293A cells were maintained in Dul-
becco’s Modified Eagle Medium with 10% FBS (D10). DC2.4 (35) and EL-4
were maintained in D10 or RPMI 1640 medium with 10% FBS (R10). All
media was from Invitrogen. For use as stimulators in CD8  T cells assays,
1–5   106 DC2.4 were infected with VACV at 5–10 PFU/cell in  200  l
of PBS at 37 C for 30–60 min with occasional shaking. After this initial in-
cubation, 9 ml R10 was added, and the incubation continued until a total
time after infection of at least 4 h. Infected cells were spun and washed, and
the appropriate number was added to T cell assays.
Synthetic peptides. Peptides were synthesized as described previously
(36) by A & A Labs, at the John Curtin School of Medical Research Bio-
molecular Resources Facility (Australian National University, Canberra,
Australia) or purchased as crude material from Mimotopes or Pepscan Sys-
tems B.V. Peptides were resuspended at 4–20 mg/ml in 100% DMSO and
diluted to required concentrations in PBS, PBS with 0.05% NP-40, or
RPMI 1640. Peptides for use as radiolabeled probes were purified to  95%
homogeneity by reversed phase HPLC, and composition was ascertained by
amino acid analysis, sequencing, and/or mass spectrometry analysis. Radio-
labeling was done using the chloramine T method (37).
Enrichment of splenic DCs. DCs were enriched from C57BL/6 mouse
spleens essentially as described previously (38). In brief, spleen fragments
were digested for 20 min at room temperature with collagenase-DNase and
treated for 5 min with EDTA. Low-density cells (including DCs) were se-
lected by centrifugation in a Hepes-buffered balanced salt solution, pH 7.2,
with 3% FCS and Nycodenz at a density of 1.077 g/cm3 (Nycomed). The
DC-enriched fraction was cultured overnight at 37 C with 5% CO2 in
DMEM (high glucose) with 10% FBS and 100 ng/ml LPS. The nonadherent
population from this culture was collected. Enriched DCs were incubated
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Mice, infections, and immunizations. Specific pathogen-free C57BL/
6 mice were obtained from Taconic, Animal Resource Centre (Perth, Aus-
tralia), and Animal Services Division, John Curtin School of Medical Re-
search. Mice were housed, and experiments were done according to the rel-
evant ethics requirements. In most experiments, mice were infected i.p.
with 106–5   107 PFU of VACV, depending on virus strain. For dermal
scarification, 10 scratches were made at the base of the tail in a crosshatch
pattern using a 21 gauge needle and a drop of VACV at 107 PFU/ml ap-
plied for 1 min before the excess was removed with a tissue. For subcutane-
ous infections, 103 PFU ECTV and 106 PFU CPXV and VACV were in-
jected in the shanks of mice. Except where stated, mice were euthanized
7 d after infection and spleens taken for analysis of CD8  T cell responses.
For DC immunization, 2.5   105 peptide-coated, spleen-derived DCs sus-
pended in PBS were injected intravenously. For ECTV challenge, DC-
immunized or control mice were anesthetized and infected intranasally with
300 PFU of ECTV in 20  l of PBS. Mice were monitored for signs of ill-
ness twice daily, and moribund animals euthanized.
It was noted that C57BL/6 mice available in Australia (from two
sources) made very high VACV-specific responses (Figs. 2–5). Mice available
in the USA had lower total VACV-specific responses in the spleen (20–25%
of CD8  T cells; unpublished data), similar to other published studies (20,
39). The relative contribution of the mapped determinants to the total CD8 
T cell response was very similar irrespective of country or source of mice.
Generation of VACV ORF library. Primary PCR products (and asso-
ciated information) representing 266 predicted ORFs of VACV, made for a
project investigating VACV protein–protein interactions by yeast 2-hybrid
(40), were a gift from B. Moss (NIAID, Bethesda, MD). These were ream-
plified by PCR using Platinum Pfx (Invitrogen) and the primers 5 -CAC-
CGAATTCCAGCTGACCACC-3  and 5 -TATTCGGATCCCCGGGAA-
TTGC-3  and cloned into the eukaryotic expression vector pcDNA3.1D/
V5-His-TOPO (Invitrogen) according to the manufacturer’s instructions.
Clones were screened by cleavage of miniprep DNA (Wizard SV 96;
Promega) with BamHI (site underlined in the aforementioned primer se-
quence) and separation on 1.2% agarose gels. This initial library was ed-
ited, with 12 duplicated ORFs being removed and four ORFs (known to
exist but missing) being added (A13L, A14.5L, A44L, and A48R); ORFs
were PCR amplified directly from crude virus stocks and cloned as de-
scribed before. The complete library comprised 258 unique clones each
representing a single predicted VACV ORF. The 5  end ( 600 bp) of
each ORF clone was sequenced using ABI BigDye Terminators reagents
and an ABI PRISM 3100 genetic analyzer (Applied Biosystems). Clones
with early terminations or frame shifts were removed and remade. Trans-
fection grade (low endotoxin) DNA for each clone was produced by
Aldevron.
Generation of 293 cells expressing mouse MHC genes. The com-
plete coding sequences for H-2Kb and Db were amplified by PCR from re-
combinant VACV encoding these products and cloned into pcDNA3.1D/
V5-His-TOPO as described before. The following primers were used:
Kb, 5 -CACCATGGTACCGTGCACGCTG-3  and TCACGCTA-
GAGAATGAGGGTC; and Db, 5 -CACCATGGGGGCGATGGCTC-3 
and 5 -TCACGCTTTACAATCTCGGAG-3 . All clones were verified by
sequencing and comparison to GenBank/EMBL/DDBJ accession nos.: Kb,
U47328; and Db, U47325. To make stable cell lines, plasmids were cleaved
with SmaI and transfected into a single well of a six-well dish of 293A cells
using Lipofectamine 2000 reagent according to the manufacturer’s instruc-
tions (Invitrogen). After overnight incubation (37 C, 9% CO2), cells were
harvested and six serial 1:5 dilutions were made in a fresh six-well plate in
medium supplemented with 0.5 mg/ml G418 (Biofluids). After several
weeks of selection and growth in G418-containing medium, transfectants
were cloned by limiting dilution (H-2 Kb) or FACS followed by single cell
deposition (H-2 Db, FACStar Plus; BD Biosciences). Potential H-2–
expressing clones were selected by staining with mAbs (HB176 supernatant
followed by rabbit anti–mouse Ig-FITC for Kb and direct FITC conjugates
for Db; BD Biosciences) and analysis on a FACSCalibur (BD Biosciences).
The clones selected were 293KbC2 and 293DbA5 and were maintained in
0.5 mg/ml G418. Expression of H-2 antigens was found to be stable for
many passages in nonselecting medium.
Transfections in 96-well format and harvesting transfectants.
293KbC2 or 293DbA5 cells were seeded in flat-bottom 96-well plates be-
tween 5 and 8   104 cells/well the night before transfection. Diluted Lipo-
fectamine 2000 (25  l/well of 1:50 dilution) was arrayed in 96-well plates and
mixed with plasmid DNA (25  l at 0.01  g/ml). These transfection mixes
were left at room temperature for 30 min before being used to replace me-
dium on the 293Kb/Db cells. After 2 h at 37 C with 5% CO2, 100  l of fresh
D10 was added to each well and the plates returned to 37 C overnight. For T
cell stimulations, transfected cells were harvested by washing wells with 50  l
PBS and incubating them with 20  l trypsin for several minutes. Cells were
collected with 100  l D10 and moved to U-bottom 96-well plates. Plates
were spun, medium and trypsin were removed, and transfectants were resus-
pended with suspensions of splenocytes or CD8  T cells to begin stimulations.
Stimulations and ICS. Splenocytes (0.2–1   106) or CD8  T cells (105,
CD8a  T Cell Isolation Kit; Miltenyi Biotec) were incubated with the fol-
lowing: (a) transfected cells (see previous paragraph), (b) synthetic peptides,
(c) DC2.4 pulsed with synthetic peptides at various concentrations, or (d)
DC2.4 infected with VACV (see Viruses and cell lines) in the wells of a 96-
well plate at 37 C and 5% CO2. Synthetic peptides (if used) were added to a
final concentration of 0.5  M; cells (except those transfected in 96-well for-
mat) were used at 1–2   105 cells per well. 10  g/ml brefeldin A was added
after 1 h, and the incubation continued for another 3–4 h. Plates were spun,
medium was removed, and cells were resuspended in 50  l of  -CD8-PE
(clone 53–6.7; BD Biosciences; some experiments used FITC or PE-Cy5)
and incubated on ice for 20 min. Cells were washed, resuspended in 50  l
of 1% paraformaldehyde, and incubated at room temperature for 20 min
before another two washes and staining with  -IFN- –allophycocyanin
(clone XMG1.2; BD Biosciences; some experiments used FITC or PE)
overnight in PBS with 0.5% saponin at 4 C. Cells were washed once before
acquisition and analysis of fluorescence using a FACSCalibur (BD Bio-
sciences). Analysis was done using Flowjo software (Tree Star Inc.); events
were gated for live lymphocytes on FSC   SSC followed by CD8  cells us-
ing CD8   SSC and displayed as CD8   IFN- . Data was recorded as
IFN-  , CD8  cells as a percentage of total CD8  cells. Backgrounds as
determined using irrelevant peptides, cells transfected with irrelevant con-
structs or uninfected cells were usually in the order of 0.1% and were sub-
tracted from the values presented for test samples.
MHC binding assays. Quantitative assays to measure the binding of pep-
tides to soluble class I molecules are based on the inhibition of binding of a
radiolabeled standard peptide (37). In brief, 1–10 nM radiolabeled peptide
was coincubated at room temperature with 1  M to 1 nM of purified class I
molecules (from EL-4) in the presence of 1  M of human  2-microglobu-
lin (Scripps Laboratories) and a cocktail of protease inhibitors. The radiola-
beled peptides were used, and their average IC50s were RGYVFQGL, 3.1
nM and SGPSNTYPEI, 4.4 nM for Kb and Db, respectively (41). After a
2-d incubation, binding of the radiolabeled peptide to the corresponding
MHC class I molecule was determined by capturing MHC–peptide com-
plexes on Greiner Lumitrac 600 microplates (Greiner Bio-one) coated with
the W6/32 antibody, and measuring bound cpm using the TopCount mi-
croscintillation counter (Packard Instrument Co.). In the case of competi-
tive assays, the concentration of peptide yielding 50% inhibition of the
binding of the radiolabeled probe peptide was calculated (IC50). Peptides
were typically tested in three or more independent experiments. Under the
conditions used, where [label]   [MHC] and IC50   [MHC], the mea-
sured IC50 values are reasonable approximations of the true Kd values (42).
Sequence comparison. ORF and determinant conservation between
poxviruses was done with the aid of poxvirus orthologous clusters (43)JEM VOL. 201, January 3, 2005 103
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maintained at the University of Victoria, Victoria, BC Canada and accessed
through the Poxvirus Bioinformatics Resource (www.poxvirus.org).
Statistical analysis. Statistical analysis was done with the aid of Prism
software (Graphpad). For comparing the means of responses or ratios, Stu-
dent’s t tests were used. For Kaplan-Meier survival analyses, p-values were
generated using the log-rank test to compare survival curves. Differences
were considered significant if p-values were  0.05.
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